Project Grant R01CA278826
Award Date 2/19/24
Completion Date 1/31/29
Dollars Obligated $582K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $107,071 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Rockefeller University, effective March 1, 2025 through February 28, 2029. The grant supports research to investigate the role of inter-organellar communication, specifically between the endoplasmic reticulum and mitochondria, in metabolic reprogramming and cellular plasticity in colorectal cancer. Key objectives include identifying the molecular mechanisms...
- This $192,888 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a research project at the University of Virginia (UVA) to investigate the use of normal colon organoids for identifying causal genetic variants associated with colorectal cancer risk. The key objectives of the project are to: 1) test the hypothesis that colorectal cancer GWAS genes are cell type-specific, and 2) determine the role of these genes within colon epithelial...
- This federal Project Grant award of $205,700 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the Sloan-Kettering Institute for Cancer Research in New York aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach to...
- This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...
- This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- The National Cancer Institute awarded a $936,746 Project Grant to Rutgers University for the research project "Cancer Cell-Intrinsic Mitochondrial Stress Responses Influence Protective Immunity" under the federal Cancer Biology Research grant program (CFDA 93.396). The goal of this 5-year project is to further understand how cancer cell mitochondrial dysfunction and stress responses affect immune responses in ovarian cancer, with a focus on a specific gene variant associated with...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...
- This federal Project Grant award of $423,084 was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to support research on the musculoskeletal cost of metastatic colorectal cancer. The award aims to identify targetable mediators of skeletal muscle and bone loss in advanced colorectal cancer, with a focus on the role of the hormone FGF21. The research is being conducted by the Trustees of Indiana University at Indiana University Indianapolis from May 2025 through...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $154,642 to the Sloan-Kettering Institute for Cancer Research in New York to conduct research on identifying conserved cancer-specific immunopeptide targets in metastatic colorectal cancer. The project aims to systematically elucidate the evolving immunopeptidome (peptides presented by HLA class I molecules) from patient-derived colorectal cancer organoids to reveal targetable...